Recent research shows that atrial fibrillation (AF), while more common in white people, is much more dangerous and deadly for black individuals. The study, published June 22 in JAMA Cardiology , showed blacks with AF were 42 percent more likely to experience heart failure and 76 percent more likely to develop coronary heart disease (CHD) … Continue reading AF comon to white but more deadly for black patients →

Heart Failure C-Pulse System Components The C-Pulse Heart Assist System leverages the known concept of counterpulsation. The C-Pulse system applies this concept in an innovative way. Through the application of a cuff wrapped around the outside of the aorta, the C-Pulse System inflates and deflates the cuff in rhythm with the natural heartbeat, applying a … Continue reading Heart Failure and C-Pulse System Sunshineheart →

Background—There is no systematic assessment of available evidence on effectiveness and comparative effectiveness of balloon dilatation and stenting for aortic coarctation. Methods and Results—We systematically searched 4 online databases to identify and select relevant studies of balloon dilatation and stenting for aortic coarctation based on a priori criteria (PROSPERO 2014:CRD42014014418). We quantitatively synthesized results for … Continue reading Is Stent better vs Balloon for aortic coarctation? →

High risk for functional mitral regurgitation, percutaneous direct annuloplasty is a feasible and safe treatment method, according to data published in theJournal of the American College of Cardiology. The annuloplasty initiated left ventricular (LV) reverse remodeling, and showed clinical improvement 6 months after treatment. Researchers of the study reported the feasibility, safety, and efficacy data … Continue reading High-Risk Functional Mitral Regurgitation and Percutaneous Direct Annuloplasty Feasible →

Samir Pancholy, M.D., an interventional cardiologist in Clarks Summit, helped introduce the nation to a less painful, safer way to insert a catheter through the wrist instead of the groin. He is breaking ground with a device that prevents blood vessels from closing after the procedure. One of the potential downsides of doing radial artery … Continue reading Cardiologist invents medical VasoBand for heart patients →

Valcare developed The Amend™ Mitral Valve Repair Annuloplasty ring, a semi-rigid, a ‘D’ shaped ring that emulates the current gold standard for patients who suffer from Mitral Valve Regurgitation (the valve that controls blood flow between the left atrium and left ventricle). In a series of cases, the ring was successfully Trans apically delivered through … Continue reading Successful completion of first phase clinical trial for Valcare Medical an Accelmed company. →

Heart failure (HF) is one of the major health challenges faced by society today, afflicting 6 million Americans, claiming hundreds of thousands of lives each year and costing more than $30 billion dollars annually [1]. With the support of a five-year, $2.86 million R01 grant from the National Heart, Lung, and Blood Institute, researchers at … Continue reading Wearable Sensing Technology for Heart Failure Patients by Georgia Tech →

The global market is expected to reach USD 2.4 Billion by 2021 from USD 0.4 Billion by 2016, at a CAGR of 42.5% from 2016 to 2021. The major driving factors are the increasing focus of the companies on clinical trials of bioabsorbable stents, increasing aging population, technological advancements, and patients’ preference for minimally invasive … Continue reading Market Worth 2.4 Billion USD by 2021 with Bioabsorbable Stents →

A study in India by IMS Health has revealed that the price of stents in their country is not the highest contributor to the overall angioplasty cost.The studyvreveals that stent prices contribute only 20 – 25% to the overall angioplasty procedure costs. It was also found that prices of stents declined by 6-10% per year … Continue reading Stent Manufacturers have Reduced Prices by 30 to 50% in the Last 4 Years Across →

Allergan plc AGN announced that FDA has accepted its 510(k) Premarket Notification Application for the XEN Glaucoma Treatment System, comprising XEN45 gel stent and XEN injector, for review. XEN45 gel stent is a minimally invasive, implantable, cross- linked gelatin shunt used to reduce intraocular pressure associated with refractory glaucoma. “We are pleased that the FDA … Continue reading FDA accepts Allergan’s 510(k) premarket notification filing for XEN glaucoma treatment system →